Read the latest Immune monitoring technology primer
Immune Monitoring Technology Primer: protein microarray (‘seromics’)
Jianda Yuan, Ena Wang and Bernard A. Fox
Read the previously published articles here.
Published on: 19 January 2016
Published on: 19 January 2016
Published on: 15 December 2015
Most accessed articles
Published on: 15 July 2013
Published on: 29 July 2013
Published on: 27 August 2013
Aims and scope
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC welcomes submissions to the following sections:
- Basic Tumor Immunology - edited by Cornelis J. Melief
- Case Reports - edited by Alfred Zippelius
- Clinical Trials Monitor - edited by Leisha A. Emens
- Clinical/Translational Cancer Immunotherapy - edited by F. Stephen Hodi
- Commentary/Editorials - edited by Christian Capitini
- Immunotherapy Biomarkers - edited by Lisa H. Butterfield
- Reviews - edited by Bernard A. Fox and Thomas F. Gajewski
Free Publication for Society Members
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts published in JITC.
SITC Best Paper Awards
Two $1,000 USD awards will be given for the JITC Best Clinical/Translational Paper and the JITC Best Basic Science Paper published in JITC.
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.
Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.